Brain & sleep Neuromodulatory nonapeptide
DSIP
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- Also known as
- Delta Sleep-Inducing Peptide
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
DSIP (delta sleep-inducing peptide) is a naturally occurring peptide sold on the "research peptide" market for sleep and stress. Its human evidence is limited to a few small, dated, inconsistent studies, and no validated mechanism or reproducible benefit has been established. As of 2026 it is not FDA-approved and not approved as a drug anywhere.
At a glance
- FDA status
- Non-FDA-approved peptide sold in the wellness/gray market
- What it is
- Naturally occurring nine-amino acid peptide linked in early research to sleep
- Research
- Human evidence is sparse, old, and inconsistent; no mechanism is validated
- Approval status
- Not approved as a drug in any country
- Evidence strength
- Low research
Summary
DSIP is a naturally occurring nine-amino-acid peptide linked to sleep in early research. Learn its history, what studies show, and its unapproved status.
What is DSIP?
DSIP, delta sleep-inducing peptide, is a naturally occurring nine-amino acid peptide first isolated decades ago from the blood of sleeping rabbits. It is sold through wellness and "research peptide" channels for sleep and stress, though its role in the body is still not well understood. It is not an approved medicine.
What is the history of DSIP?
DSIP was discovered in the 1970s out of a long-standing question in sleep science: whether sleep is driven by a chemical that circulates in the blood. Working in Switzerland, the physiologist Marcel Monnier and colleagues ran cross-circulation experiments in rabbits, electrically stimulating a sleep-related region of the brain in one animal and passing its blood to a second, which then showed the slow, high-amplitude "delta" brain waves of deep sleep. That pointed to a sleep-promoting substance carried in the blood.
In 1977, Guido Schoenenberger, Monnier, and their co-workers isolated and synthesized that substance, a nine-amino-acid peptide they named delta sleep-inducing peptide after the delta-wave sleep it was linked to. Having a synthetic version made the peptide available for wider study.
Over the following decades, researchers looked beyond sleep, exploring possible roles in stress, body temperature, pain, and antioxidant activity, but the findings never converged into a validated mechanism or an approved therapy. DSIP was later shown to occur naturally in humans as well as animals. Despite nearly fifty years of study, it remains an experimental compound rather than a medicine, sold today through wellness and "research peptide" channels.
How does it work?
DSIP has been proposed to play roles in:
- Regulating sleep
- Modulating the body's stress (HPA-axis) responses
- Acting as an antioxidant
It has no validated receptor or defined mechanism. The sleep association that gave it its name comes from early animal work that has not resolved into a clear understanding of how, or whether, it influences human sleep. This describes a proposed mechanism, separate from any demonstrated benefit.
Is it FDA-approved?
Safety note
Status: Non-FDA-approved peptide sold in the wellness/gray market
Category: Wellness and performance · Primary body area: Brain & sleep
No. DSIP is not approved by the FDA and is not approved as a drug in any country; it is sold only through research and gray-market channels and is not on FDA compounding lists. As a neutral regulatory note, a related sleep compound was reviewed at a 2026 FDA compounding advisory meeting and received an unfavorable vote.
What does the research show?
Editor’s note
Evidence strength: Low research
The human data are limited to sparse, dated, low-quality studies without reproducible efficacy, and no mechanism has been validated.
The human evidence is thin and old. A small number of studies from the 1980s and 1990s examined DSIP in insomnia, chronic pain, and withdrawal states and reported inconsistent findings; most were small and uncontrolled, and no modern, well-conducted trials have established a reproducible benefit. There is no sound human evidence that DSIP improves sleep or stress.
Sources: the small human studies of DSIP from the 1980s are indexed on PubMed, including a double-blind insomnia study (Schneider-Helmert & Schoenenberger, 1981, DOI 10.1007/BF01971753), a chronic-pain pilot study (Larbig et al., 1984, DOI 10.1159/000115716), and an open-label alcohol- and opiate-withdrawal study (Dick et al., 1984, DOI 10.1159/000115715); and reference literature on therapeutic peptides noting its preclinical status (Journal of the AAOS Global Research & Reviews, 2025, DOI: 10.5435/JAAOSGlobal-D-25-00236). This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- PMID 862769
- [2]
- [3]
- [4]
- [5]
Compare every peptide’s status in the peptide regulatory status database
More for Brain & sleep
View all brain & sleep peptides →- FDA-approved Brain & sleep
Bremelanotide
Bremelanotide is a synthetic seven-amino acid peptide that activates melanocortin receptors in the brain to increase sexual desire, unlike blood-flow drugs such as sildenafil. In the two RECONNECT phase 3 trials of 1,267 premenopausal women with hypoactive sexual desire disorder (HSDD), it raised the desire score 0.35 points more than placebo and reduced desire-related distress 0.33 points more (both P<.001) over 24 weeks. It is FDA-approved as Vyleesi, a prescription self-injection for acquired, generalized HSDD. Versions sold online as PT-141 are not the FDA-approved product and are not quality-controlled.
- Not FDA-approved Brain & sleep
Cerebrolysin
Cerebrolysin is a preparation of small peptides and amino acids derived from pig brain, used in some countries for stroke and dementia and sold elsewhere for cognition. It has been tested in many human trials, but systematic reviews found no clear benefit on survival or function after stroke and only a weak, low-quality signal in vascular dementia. As of 2026 it is not FDA-approved in the United States.
- In clinical trials Brain & sleep
Davunetide
Davunetide is an investigational neuroprotective peptide derived from a brain protein, studied as an intranasal treatment for the rare neurodegenerative disease progressive supranuclear palsy. Its large pivotal trial clearly failed, showing no benefit over placebo, and earlier signals in other conditions were small and never confirmed. As of 2026 it is not approved.
- Not FDA-approved Brain & sleep
Dihexa
the Research Peptide
Dihexa is an experimental cognition peptide derived from angiotensin IV, sold on the "research peptide" market for brain function. Its evidence is entirely preclinical, with no human trials, and a key paper describing its proposed mechanism has been retracted. As of 2026 it is not FDA-approved or approved anywhere.
- Not FDA-approved Brain & sleep
Epitalon
Epitalon is a synthetic four-amino acid peptide based on a pineal-gland extract, sold on the "research peptide" market for anti-aging and sleep. Its human evidence is limited to older studies from a single Russian research group, not independently replicated. As of 2026 it is not FDA-approved, though a 2026 FDA advisory committee gave a non-binding favorable vote toward allowing it to be compounded.
- In clinical trials Brain & sleep
Nnz-2591
NNZ-2591 is an investigational oral peptide related to a natural fragment of IGF-1, developed by Neuren Pharmaceuticals for several rare genetic neurodevelopmental disorders including Phelan-McDermid, Rett, and Angelman syndromes. Its published human evidence is an open-label (uncontrolled) Phase 2 trial reporting broad improvement, and a placebo-controlled Phase 3 is under way. As of 2026 it is not approved.